^
    Back
    Association details:
    Biomarker:SMAD4 mutation
    Cancer:Pancreatic Cancer
    Drug Class:Immunotherapy
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C4 – Case Studies
    New
    Source:
    Front Immunol
    Title:

    Successful Immunotherapy for Pancreatic Cancer in a Patient With TSC2 and SMAD4 Mutations: A Case Report

    Published date:
    11/22/2021
    Excerpt:
    In this case, the effect of immunotherapy combined with chemotherapy seems to be very effective. We also established a hypothesis that the SMAD4 and TSC2 mutations improved the efficacy of immunotherapy, prolonging the survival of patients.
    DOI:
    10.3389/fimmu.2021.785400